@article{article_1798434, title={Pharmacotherapy in Interstitial Cystitis/ Painful Bladder Syndrome}, journal={Fabad Eczacılık Bilimler Dergisi}, volume={50}, pages={867–880}, year={2025}, DOI={10.55262/fabadeczacilik.1798434}, author={Denizaltı, Merve and Kandilci, N. Tuğba}, keywords={Interstitial cystitis/ Painful bladder syndrome, inflammation, conservative treatment, oral treatment, intravesical treatment}, abstract={Interstitial cystitis/ Painful bladder syndrome is a chronic disease characterized by suprapubic pain associated with bladder filling, accompanied by an overactive detrusor and inflammation of the bladder. Although the etiology and pathophysiology of this disease are not precisely known, many pathophysiological theories have been proposed, such as the glycosaminoglycan theory, altered permeability, neural regulation, mast cell and neuroendocrine theories. Different treatment methods have been developed based on these theories. The developed pharmacotherapies can be classified as conservative treatment, oral treatment, intravesical treatment and current treatment methods. Agents used in oral treatment include pentosan polysulfate, tricyclic antidepressants, histamine receptor antagonists, immunosuppressants and AQX-1125 (Rosiptor); while agents used in intravesical therapy include dimethyl sulfoxide, lidocaine, heparin and pentosan polysulfate, chondroitin sulfate and hyaluronic acid, and bacillus calmette-guerin. The use of botulinum toxin A (BTX-A) has also been approved. Finally, current treatment methods include phosphodiesterase-5 inhibitors, monoclonal antibodies, cannabinoids, and liposome use. The goal of most treatments is to control symptoms.}, number={3}, publisher={FABAD Ankara Eczacılık Bilimleri Derneği}